Raclopride - Metabolism
Research News and Information

Sunday, November 22, 2009

C957T polymorphism of dopamine D2 receptor gene affects striatal DRD2 in vivo availability by changing the receptor affinity.

29 Sep 2009 The C957T polymorphism of the human dopamine D2 receptor gene (DRD2) regulates DRD2 availability in striatum in vivo. Specifically, the T allele predicts high DRD2 availability in healthy volunteers (T/T>T/C>C/C). However, this finding was ... Read more...

Dopaminergic activity in depressed smokers: a positron emission tomography study.

30 Jul 2009 Tobacco dependence is highly prevalent in depressed patients. We assessed changes in [(11)C]-raclopride binding potential (BP) using positron emission tomography (PET) before and after the oral administration of d-amphetamine in healthy controls and ... Read more...

Abnormal striatal and thalamic dopamine neurotransmission: Genotype-related features of dystonia.

14 Jun 2009 OBJECTIVE: To determine whether changes in D(2) receptor availability are present in carriers of genetic mutations for primary dystonia. METHODS: Manifesting and nonmanifesting carriers of the DYT1 and DYT6 dystonia mutations were scanned with ... Read more...

Latest indexed articles for 'Raclopride - Metabolism'

These are the very latest articles for this heading:

• C957T polymorphism of dopamine D2 receptor gene affects striatal DRD2 in vivo availability by changing the receptor affinity. 29 Sep 2009
• Dopaminergic activity in depressed smokers: a positron emission tomography study. 30 Jul 2009
• Abnormal striatal and thalamic dopamine neurotransmission: Genotype-related features of dystonia. 14 Jun 2009
• Cue-induced dopamine release predicts cocaine preference: positron emission tomography studies in freely moving rodents. 11 May 2009
• Regional analysis of age-related decline in dopamine transporters and dopamine D2-like receptors in human striatum. 30 Mar 2009
• Striatal extracellular dopamine levels and behavioural reversal in MPTP-lesioned mice. 23 Mar 2009
• Sensitivity of older patients to antipsychotic motor side effects: a PET study examining potential mechanisms. 27 Feb 2009
• Striatal dopamine responses to intranasal cocaine self-administration in humans. 25 Feb 2009
• Receptor occupancy and brain free fraction. 19 Jan 2009
• Nicotine- and methamphetamine-induced dopamine release evaluated with in-vivo binding of radiolabelled raclopride to dopamine D2 receptors: comparison with in-vivo microdialysis data. 18 Jan 2009
• Extrastriatal dopamine D2 receptor binding modulates intraindividual variability in episodic recognition and executive functioning. 17 Jan 2009
• Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naive Parkinson's disease. 17 Jan 2009
• Mesolimbic functional magnetic resonance imaging activations during reward anticipation correlate with reward-related ventral striatal dopamine release. 22 Dec 2008
• Striatal and extrastriatal D2/D3-receptor-binding properties of ziprasidone: a positron emission tomography study with [18F]Fallypride and [11C]raclopride (D2/D3-receptor occupancy of ziprasidone). 29 Nov 2008
• Theta burst stimulation-induced inhibition of dorsolateral prefrontal cortex reveals hemispheric asymmetry in striatal dopamine release during a set-shifting task: a TMS-[(11)C]raclopride PET study. 30 Oct 2008
• A method based on Monte Carlo simulations and voxelized anatomical atlases to evaluate and correct uncertainties on radiotracer accumulation quantitation in beta microprobe studies in the rat brain. 31 Aug 2008
• Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum. 25 Aug 2008
• Sleep deprivation decreases binding of [11C]raclopride to dopamine D2/D3 receptors in the human brain. 18 Aug 2008
• D2-receptor upregulation is dependent upon temporal course of D2-occupancy: a longitudinal [11C]-raclopride PET study in cats. 4 Aug 2008
• Decrease of D2 receptor binding but increase in D2-stimulated G-protein activation, dopamine transporter binding and behavioural sensitization in brains of mice treated with a chronic escalating dose 'binge' cocaine administration paradigm. 28 Jul 2008

See a longer list of these articles.

Technical information about 'Raclopride'

Definition: A substituted benzamide that has antipsychotic properties. It is a dopamine D2 receptor (see RECEPTORS, DOPAMINE D2) antagonist.

Chemical name: Benzamide, 3,5-dichloro-N-((1-ethyl-2-pyrrolidinyl)-methyl)-2-hydroxy-6-methoxy-

Registry Number: 84225-95-6

Descriptor UI: D020891

Alternative terms: Raclopride; FLB-472; FLB 472; FLB472; Raclopride C11; C11, Raclopride; FLA-870; FLA 870; FLA870;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Pharmacological Action: Antipsychotic Agents; Dopamine Antagonists;

Tree Number: D02.065.277.761; D02.241.223.100.120.761;

History Note: 2000; use RACLOPRIDE 1985-1999